A Phase 2 interventional study of Psilocybin in Borderline Personality Disorder and Major Depressive Disorder, sponsored by University of Chicago. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University of Chicago · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Borderline Personality Disorder with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Borderline Personality Disorder · United States.
Among the 81 studies in Borderline Personality Disorder with a site in United States, this one is the 64th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2023, is one of 16 in phase 2, and was the 64th registered.
279 studies on the registry are indexed under Borderline Personality Disorder; 70 are open to participants now.
Browse Borderline Personality Disorder studies →15 of the 81 studies in Borderline Personality Disorder with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 22–65
Mclean Hospital · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18–60
University of California, Los Angeles · Sites in United States
Ages 18–65
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Borderline Personality Disorder studies recruiting now, 18 (37%) set no upper age limit and 30 (61%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 19 · Phase 3 6 · Phase 4 6
First in 1997; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 70 across 222 interventional studies indexed under Borderline Personality Disorder.
Median enrollment 56 across the 71 interventional studies, 48 across the 7 observational. Of the 57 that completed or were terminated, 22 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 81 have an industry lead sponsor. The 10 most frequent:
University of Chicago is the lead sponsor of 926 studies on the registry; 187 are open to participants now.
Of its 103 completed or terminated interventional studies of FDA-regulated products, 72 (70%) have results posted.
University of Chicago has 4 studies filed under Borderline Personality Disorder — fewer than ten, so there is no comparison to draw.
7 of the studies in Borderline Personality Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04870255Stanford UniversityTreatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS | 2026-12 |
| NCT05651295Matthew Southward, PhDA Precision Medicine Approach to Target Engagement for Emotion Regulation | 2026-12-31 |
| NCT06683014Yale UniversityMDMA in Borderline Personality Disorder | 2027-06 |
| NCT07460947Mclean HospitalA Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder | 2027-06 |
| NCT06772831Icahn School of Medicine at Mount SinaiCognitive Reappraisal Training for Borderline Personality (BPD) | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 81 studies in Borderline Personality Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
The primary objective of the proposed study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD). Ten subjects with MDD and BPD will receive a single 25 mg oral dose of psilocybin. The hypothesis to be tested is that psilocybin will result significant reduction in symptoms of both MDD and BPD after 1 week and sustained for 4 weeks compared to baseline (improvement in symptoms will be indicated by lower scores on established outcome measures of MDD and BPD symptoms that have been used in prior studies).
The criteria were revised on the registry on Oct 29, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single 25 mg capsule oral dose of psilocybin
Drug: Psilocybin
Psilocybin 25mg capsule
Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
The MADRS is a 10-item, clinician-administered scale that assesses depression symptoms during the last seven days. Each item is rated on a scale from 0 to 6, with 0 being "normal/not present" and 6 being "extreme." Scores from each item are added together to reach a total score. Higher total scores (ranging from 0-60) indicate higher severity levels of depression, while a score of 0 indicates no depressive symptoms. Change in scores from baseline to Visit 5 will be reported.
Time frame: Baseline/Visit 1/Week 0 to Visit 5/Week 5
Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS) Total Score
The BPD-SAS covers a two-week time frame and contains 11 items, each representing a different symptom of BPD. Each item is rated on a five-point anchored rating scale of 0-4, with 0 representing no symptoms and 4 representing extreme symptoms. Total scores are computed by adding up the scores for each item (total scores range from 0-44) with higher scores indicating higher levels of severity of BPD symptoms. Change in the total score from Baseline to Visit 5 will be reported.
Time frame: Baseline/Visit 1/Week 0 to Visit 5/Week 5
Clinical Global Impression - Improvement Scale (CGI-I)
A clinician administered, single item scale measuring overall improvement of global severity of psychiatric illness. The scale itself assesses overall disorder improvement since baseline on a scale from 1 to 7 with 1 being "Very much improved" and 7 being "Very much worse." Results are reported as the scores from participants on Visit 5.
Time frame: Visit 2/Week 1 to Visit 5/Week 5
| Milestone | Experimental: Psilocybin |
|---|---|
| Started | 9 |
| Completed | 7 |
| Not completed | 2 |
| Withdrew: 2 participants did not complete all follow-up visits and were not included in the final analysis | 2 |
The MADRS is a 10-item, clinician-administered scale that assesses depression symptoms during the last seven days. Each item is rated on a scale from 0 to 6, with 0 being "normal/not present" and 6 being "extreme." Scores from each item are added together to reach a total score. Higher total scores (ranging from 0-60) indicate higher severity levels of depression, while a score of 0 indicates no depressive symptoms. Change in scores from baseline to Visit 5 will be reported.
| score on a scale | Experimental: Psilocybin |
|---|---|
| Baseline | 28.56 ± 4.53 |
| Visit 5 | 17.22 ± 10.39 |
The BPD-SAS covers a two-week time frame and contains 11 items, each representing a different symptom of BPD. Each item is rated on a five-point anchored rating scale of 0-4, with 0 representing no symptoms and 4 representing extreme symptoms. Total scores are computed by adding up the scores for each item (total scores range from 0-44) with higher scores indicating higher levels of severity of BPD symptoms. Change in the total score from Baseline to Visit 5 will be reported.
| score on a scale | Experimental: Psilocybin |
|---|---|
| Baseline | 32.67 ± 4.18 |
| Visit 5 | 28.11 ± 8.98 |
A clinician administered, single item scale measuring overall improvement of global severity of psychiatric illness. The scale itself assesses overall disorder improvement since baseline on a scale from 1 to 7 with 1 being "Very much improved" and 7 being "Very much worse." Results are reported as the scores from participants on Visit 5.
| Participants | Experimental: Psilocybin |
|---|---|
| Very much improved | 0 |
| Much improved | 3 |
| Minimally improved | 3 |
| No change | 0 |
| Minimally worse | 1 |
| Much worse | 0 |
| Very much worse | 0 |
Collected over Adverse event data were collected from enrollment until end of follow-up, up to Visit 5/Week 5.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Psilocybin | 0/9 (0%) | 1/9 (11.1%) | 7/9 (77.8%) |
| Event | Experimental: Psilocybin |
|---|---|
| Psychiatric Hospitalization After Study Drug AdministrationPsychiatric disorders | 1/9 |
| Event | Experimental: Psilocybin |
|---|---|
| NauseaGastrointestinal disorders | 4/9 |
| Cried/Felt EmotionalPsychiatric disorders | 3/9 |
| Passive Suicidal Ideation at BaselinePsychiatric disorders | 3/9 |
| Anxious Before DosePsychiatric disorders | 2/9 |
| DizzinessNervous system disorders | 1/9 |
| Fatigue/DrowsinessNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/9 |
| Age, Categorical(Participants) | Experimental: Psilocybin |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 9 |
| >=65 years | 0 |
| Age, Continuous(years) | Experimental: Psilocybin |
|---|---|
| Mean | 31.33 ± 13.45 |
| Sex/Gender, Customized(Participants) | Experimental: Psilocybin |
|---|---|
| Female | 4 |
| Male | 3 |
| Other | 2 |
| Race (NIH/OMB)(Participants) | Experimental: Psilocybin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 7 |
| More than one race | 2 |
| Unknown or Not Reported | 0 |
| Age of Onset of Borderline Personality Disorder (BPD) Symptoms(years) | Experimental: Psilocybin |
|---|---|
| Mean | 15.88 ± 4.05 |
| Age of Onset of Major Depressive Disorder (MDD) Symptoms(years) | Experimental: Psilocybin |
|---|---|
| Mean | 13.25 ± 3.28 |
| History of Illicit Psilocybin Usage(Participants) | Experimental: Psilocybin |
|---|---|
| Yes | 4 |
| No | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2023 to primary completion in Dec 2025, 25 months.
Results were first posted in Oct 2026, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
Borderline Personality Disorder →